{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:41:25Z","timestamp":1783579285646,"version":"3.55.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T00:00:00Z","timestamp":1508198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Lilly Research Laboratories"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>Sclerostin (SOST), a glycoprotein primarily derived from osteocytes, is an important regulator of bone remodeling. Osteogenesis imperfecta (OI) is a heritable disorder of bone characterized by low bone mass, bone fragility, recurrent fractures, and bone deformities. Altered SOST-mediated signaling may have a role in pathogenesis of type I collagen-related OI; however, this has not been evaluated in humans. We measured serum SOST levels in adults with OI who were enrolled in a randomized, placebo-controlled clinical trial that evaluated the effects of osteoanabolic therapy with teriparatide. Compared with age- and sex-matched control participants, mean SOST levels were lower in those with type I or types III\/VI OI (p\u2009&amp;lt;\u20090.0001). Receiver operating curve analysis revealed that sclerostin alone or sclerostin plus bone mineral content discriminated patients with OI from controls (area under the curve 0.80 and 0.87, respectively). SOST levels increased in the group of patients with type I OI during therapy with teriparatide (compared with placebo, p\u2009=\u20090.01). The increase was significant at 6, 12, and 24 months of therapy (p\u2009\u2264\u20090.02) and was apparent as early as 3 months (p\u2009=\u20090.06). The magnitude of increases in SOST levels during therapy was inversely correlated with increases in vertebral volumetric bone mineral density (vBMD). Overall, these results suggest that: 1) SOST regulation is fundamentally altered in osteogenesis imperfecta; 2) serum SOST levels could be a biomarker of OI in adults; and 3) alterations in SOST may help predict the response to anabolic therapies in OI. \u00a9 2017 American Society for Bone and Mineral Research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.3312","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T10:56:40Z","timestamp":1508237800000},"page":"307-315","source":"Crossref","is-referenced-by-count":16,"title":["Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy"],"prefix":"10.1093","volume":"33","author":[{"given":"Lindsey","family":"Nicol","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of EndocrinologyOregon Health & Sciences UniversityPortlandORUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of BiostatisticsOregon Health & Sciences UniversityPortlandORUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosamund","family":"Smith","sequence":"additional","affiliation":[{"name":"Lilly Research LaboratoriesIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sloan","sequence":"additional","affiliation":[{"name":"Lilly Research LaboratoriesIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandesh CS","family":"Nagamani","sequence":"additional","affiliation":[{"name":"Texas Children's HospitalHoustonTXUSA"},{"name":"Department of Molecular and Human GeneticsBaylor College of MedicineHoustonTXUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Department of Bone and Osteogenesis ImperfectaKennedy Krieger InstituteBaltimoreMDUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Lee","sequence":"additional","affiliation":[{"name":"Texas Children's HospitalHoustonTXUSA"},{"name":"Department of Molecular and Human GeneticsBaylor College of MedicineHoustonTXUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Orwoll","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of EndocrinologyOregon Health & Sciences UniversityPortlandORUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,10,17]]},"reference":[{"issue":"20","key":"2024021014392795000_jbmr3312-bib-0001","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"issue":"23","key":"2024021014392795000_jbmr3312-bib-0002","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J"},{"issue":"10)","key":"2024021014392795000_jbmr3312-bib-0003","doi-asserted-by":"crossref","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","article-title":"Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway","volume":"6","author":"Wijenayaka","year":"2011","journal-title":"PLoS One"},{"key":"2024021014392795000_jbmr3312-bib-0004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","article-title":"Role and mechanism of action of sclerostin in bone","volume":"96","author":"Delgado-Calle","year":"2017","journal-title":"Bone"},{"key":"2024021014392795000_jbmr3312-bib-0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","article-title":"Effects of sclerostin antibodies in animal models of osteoporosis","volume":"96","author":"Ominsky","year":"2017","journal-title":"Bone"},{"issue":"9","key":"2024021014392795000_jbmr3312-bib-0006","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J Biol Chem"},{"issue":"1","key":"2024021014392795000_jbmr3312-bib-0007","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bone.2011.10.025","article-title":"Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading","volume":"50","author":"Tu","year":"2012","journal-title":"Bone"},{"key":"2024021014392795000_jbmr3312-bib-0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bone.2016.01.024","article-title":"Successful induction of sclerostin in human-derived fibroblasts by 4 transcription factors and its regulation by parathyroid hormone, hypoxia, and prostaglandin E2","volume":"85","author":"Fujiwara","year":"2016","journal-title":"Bone"},{"issue":"2","key":"2024021014392795000_jbmr3312-bib-0009","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone","volume":"37","author":"Keller","year":"2005","journal-title":"Bone"},{"issue":"11","key":"2024021014392795000_jbmr3312-bib-0010","doi-asserted-by":"crossref","first-page":"E1848","DOI":"10.1210\/jc.2011-1534","article-title":"Acute decline in serum sclerostin in response to PTH infusion in healthy men","volume":"96","author":"Yu","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2024021014392795000_jbmr3312-bib-0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bone.2016.10.008","article-title":"Sclerostin's role in bone's adaptive response to mechanical loading","volume":"96","author":"Galea","year":"2017","journal-title":"Bone"},{"issue":"3","key":"2024021014392795000_jbmr3312-bib-0012","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"5","key":"2024021014392795000_jbmr3312-bib-0013","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"2024021014392795000_jbmr3312-bib-0014","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2024021014392795000_jbmr3312-bib-0015","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2011-3419","article-title":"Serum sclerostin and risk of hip fracture in older Caucasian women","volume":"97","author":"Arasu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024021014392795000_jbmr3312-bib-0016","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/jbmr.1718","article-title":"High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study","volume":"27","author":"Ardawi","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024021014392795000_jbmr3312-bib-0017","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jbmr.2342","article-title":"Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women","volume":"30","author":"Reppe","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024021014392795000_jbmr3312-bib-0018","doi-asserted-by":"crossref","first-page":"18789","DOI":"10.3390\/ijms151018789","article-title":"Cartilage turnover reflected by metabolic processing of type II collagen: a novel marker of anabolic function in chondrocytes","volume":"15","author":"Gudmann","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"10028","key":"2024021014392795000_jbmr3312-bib-0019","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"2024021014392795000_jbmr3312-bib-0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"issue":"5","key":"2024021014392795000_jbmr3312-bib-0021","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1210\/endo.143.5.8807","article-title":"Osteoblastic response to the defective matrix in the osteogenesis imperfecta murine (oim) mouse","volume":"143","author":"Kalajzic","year":"2002","journal-title":"Endocrinology"},{"issue":"5","key":"2024021014392795000_jbmr3312-bib-0022","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2353\/ajpath.2010.090704","article-title":"Immature osteoblast lineage cells increase osteoclastogenesis in osteogenesis imperfecta murine","volume":"176","author":"Li","year":"2010","journal-title":"Am J Pathol"},{"issue":"3","key":"2024021014392795000_jbmr3312-bib-0023","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH704>3.0.CO;2-U","article-title":"A light and electron microscopic study of osteogenesis imperfecta bone samples, with reference to collagen chemistry and clinical phenotype","volume":"192","author":"Sarathchandra","year":"2000","journal-title":"J Pathol"},{"issue":"6","key":"2024021014392795000_jbmr3312-bib-0024","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","article-title":"Static and dynamic bone histomorphometry in children with osteogenesis imperfecta","volume":"26","author":"Rauch","year":"2000","journal-title":"Bone"},{"issue":"5","key":"2024021014392795000_jbmr3312-bib-0025","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","article-title":"Sclerostin antibody treatment improves the bone phenotype of Crtap(-\/-) mice, a model of recessive osteogenesis imperfecta","volume":"31","author":"Grafe","year":"2016","journal-title":"J Bone Miner Res"},{"key":"2024021014392795000_jbmr3312-bib-0026","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bone.2017.04.016","article-title":"Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta","volume":"101","author":"Little","year":"2017","journal-title":"Bone"},{"issue":"1","key":"2024021014392795000_jbmr3312-bib-0027","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024021014392795000_jbmr3312-bib-0028","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024021014392795000_jbmr3312-bib-0029","doi-asserted-by":"crossref","first-page":"E920","DOI":"10.1210\/jc.2013-3852","article-title":"Circulating sclerostin in children and young adults with heritable bone disorders","volume":"99","author":"Palomo","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024021014392795000_jbmr3312-bib-0030","doi-asserted-by":"crossref","first-page":"E311","DOI":"10.1210\/jc.2013-2244","article-title":"Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta","volume":"99","author":"Kocijan","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024021014392795000_jbmr3312-bib-0031","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest"},{"issue":"1","key":"2024021014392795000_jbmr3312-bib-0032","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1359\/jbmr.061011","article-title":"Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis","volume":"22","author":"Keaveny","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024021014392795000_jbmr3312-bib-0033","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S8756-3282(03)00210-2","article-title":"Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography","volume":"33","author":"Crawford","year":"2003","journal-title":"Bone"},{"issue":"11","key":"2024021014392795000_jbmr3312-bib-0034","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology"},{"issue":"4","key":"2024021014392795000_jbmr3312-bib-0035","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1210\/jc.2009-2283","article-title":"Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women","volume":"95","author":"Mirza","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024021014392795000_jbmr3312-bib-0036","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00198-011-1669-z","article-title":"Sclerostin levels during growth in children","volume":"23","author":"Kirmani","year":"2012","journal-title":"Osteoporos Int"},{"key":"2024021014392795000_jbmr3312-bib-0037","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bone.2016.12.004","article-title":"Hormonal and systemic regulation of sclerostin","volume":"96","author":"Drake","year":"2017","journal-title":"Bone"},{"issue":"1","key":"2024021014392795000_jbmr3312-bib-0038","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2011-2152","article-title":"Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults","volume":"97","author":"Amrein","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024021014392795000_jbmr3312-bib-0039","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jbmr.217","article-title":"Relation of age, gender, and bone mass to circulating sclerostin levels in women and men","volume":"26","author":"Modder","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024021014392795000_jbmr3312-bib-0040","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1210\/jc.2013-2113","article-title":"Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women","volume":"98","author":"Durosier","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024021014392795000_jbmr3312-bib-0041","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/jbmr.546","article-title":"Association between sclerostin and bone density in chronic spinal cord injury","volume":"27","author":"Morse","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024021014392795000_jbmr3312-bib-0042","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s002239900571","article-title":"The microscopic structure of bone in normal children and patients with osteogenesis imperfecta: a survey using backscattered electron imaging","volume":"64","author":"Jones","year":"1999","journal-title":"Calcif Tissue Int"},{"key":"2024021014392795000_jbmr3312-bib-0043","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bone.2016.10.008","article-title":"Sclerostin's role in bone's adaptive response to mechanical loading","volume":"96","author":"Galea","year":"2017","journal-title":"Bone"},{"issue":"6","key":"2024021014392795000_jbmr3312-bib-0044","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive transforming growth factor-beta signaling is a common mechanism in osteogenesis imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat Med"},{"issue":"7","key":"2024021014392795000_jbmr3312-bib-0045","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1172\/JCI92617","article-title":"Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis","volume":"127","author":"Joeng","year":"2017","journal-title":"J Clin Invest"},{"key":"2024021014392795000_jbmr3312-bib-0046","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bone.2013.12.020","article-title":"Altered lacunar and vascular porosity in osteogenesis imperfecta mouse bone as revealed by synchrotron tomography contributes to bone fragility","volume":"61","author":"Carriero","year":"2014","journal-title":"Bone"},{"issue":"11","key":"2024021014392795000_jbmr3312-bib-0047","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1210\/jc.2010-0720","article-title":"Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women","volume":"95","author":"Drake","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024021014392795000_jbmr3312-bib-0048","first-page":"866","article-title":"Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone","volume":"35","author":"Piemonte","year":"2012","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2024021014392795000_jbmr3312-bib-0049","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1359\/jbmr.070804","article-title":"Control of the SOST bone enhancer by PTH using MEF2 transcription factors","volume":"22","author":"Leupin","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024021014392795000_jbmr3312-bib-0050","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1530\/EJE-10-0699","article-title":"Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls","volume":"163","author":"van Lierop","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"2024021014392795000_jbmr3312-bib-0051","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial","volume":"32","author":"Glorieux","year":"2017","journal-title":"J Bone Miner Res"},{"key":"2024021014392795000_jbmr3312-bib-0052","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bone.2016.10.012","article-title":"Sclerostin measurement in human disease: validity and current limitations","volume":"96","author":"Costa","year":"2017","journal-title":"Bone"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.3312","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/2\/307\/56654023\/jbmr3312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/2\/307\/56654023\/jbmr3312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:00:20Z","timestamp":1710342020000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/33\/2\/307-315\/7605792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,17]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,10,17]]},"published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3312","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2,1]]},"published":{"date-parts":[[2017,10,17]]}}}